World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF SQUAMOUS CELL CARCINOMA USING SIMILAR MOLECULE – TARCEVA

Dr. Syed Ahmed Hussain*, Arshiya Tarannum*, Umaima Batool Osmani, Raheem Unnisa Shaik, Maimuna Fatima, Faheem Unnisa and Nazneen

ABSTRACT

Aim: This study aims to evaluate the cytotoxic effects of the epidermal growth factor receptor (EGFR) inhibitor, Tarceva (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine), in comparison with the chemotherapeutic agent Cisplatin in kidney cancer cell lines. Objective: The primary objective is to assess the efficacy of Tarceva against various concentrations (1, 5, and 10 µM) and to determine its impact on cell viability using multiple assays, including MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH cytotoxicity assays. Research: The study utilized five different assays to measure cell viability and cytotoxicity, analyzing the responses of kidney cancer cell lines to Tarceva and Cisplatin. Results indicated a concentration-dependent decrease in cell viability for both drugs, with Tarceva showing significant cytotoxic effects, particularly at higher concentrations. The MTT assay results revealed cell viability percentages of 87.3%, 65.1%, and 39.6% for Tarceva at 1, 5, and 10 µM, respectively, compared to the control. Conclusion: Tarceva demonstrates promising cytotoxic effects against kidney cancer cell lines, warranting further investigation into its clinical potential as a therapeutic option, particularly in combination therapies with Cisplatin.

[Full Text Article]   [Download Certificate]